The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the landscape of Alzheimer’s disease treatments. For the first time, patients have the option to take a drug that ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Leqembi and Kisunla, he added, provide “strong support for our hypothesis that intervening when amyloid beta plaques are at the very earliest stage, long before symptoms arise, could prevent ...

A new blood test is being trialed in the UK to detect the early signs of dementia. It is hoped it could identify patients ...

President Donald Trump's administration has rescinded an order freezing spending on federal grants. Robert F. Kennedy Jr.

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...